Previous PostMaaT Pharma Launches European Clinical Trial in Acute Graft-versus-Host Disease
Next PostASH 2017: ASH 2017: Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in AML patients undergoing intensive treatment (ODYSSEE study): First results of a prospective multicenter trial
